VIROGENOMICS BIODEVELOPMENT, INC.
Portland, OR · Biotech · Private
DRhQ, a biological therapeutic molecule that binds to the MIF receptor CD74 to inhibit MIF signaling and reduce neuroinflammation in progressive multiple sclerosis
virogenomics.com →- Grants
- $9.6M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction | $224,886 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | $224,796 | |
| Federal grant | Department of Health and Human Services · Phase I · Sensitive Single Cell PhosphoCount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia | $299,931 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DR?1-MOG-35-55 for treatment of DR2 negative MS subjects | $1,450,053 | |
| Federal grant | Department of Health and Human Services · Phase I · DRα1-MOG: A Novel Immunomodulatory Therapeutic for Stroke | $299,186 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | $747,347 | |
| Federal grant | Department of Health and Human Services · Phase I · DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder | $299,560 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing novel fibrillin biomarkers for aortic disease | $268,643 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | $2,991,622 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | $996,926 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | $996,486 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder | $405,334 | |
| Federal grant | Department of Health and Human Services · Phase I · Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signaling | $399,889 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3274 | Ibex Investment Holdings LLC | — | $5.0M |
| 3275 | Lucidicor Inc. | — | — |
| 3276 | DIVINER THERAPEUTICS, LLC | — | — |
| 3277 | VIROGENOMICS BIODEVELOPMENT, INC. | — | — |
| 3278 | ENZERNA BIOSCIENCES LLC | — | — |
| 3279 | Auratus Bio LLC | — | — |
| 3280 | ASKO THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Viral Detectionapplication
- Compositions And Methods For Viral Detectionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.